Paper Review Records
All Paper Review Records
25 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
26
days
The case for targeting enhancer regions in high‐risk TCF3::HLF‐positive B‐cell acute lymphoblastic leukemia
Authors
Zahra Sheybani; Charles E. de BockShow moreShow less
Affiliations
1. Children's Cancer Institute Minderoo Children's Comprehensive Cancer Centre Randwick New South Wales Australia; 2. School of Clinical Medicine, Faculty of Medicine UNSW Sydney Sydney New South Wales AustraliaShow moreShow less
78
days
Validation of the new IMS/IMWG consensus genomic staging (CGS) of high‐risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients
Authors
Efstathios Kastritis; Charalampos Filippatos; Maria Gavriatopoulou; Foteini Theodorakakou; Eirini Solia; Ioannis Ntanasis‐Stathopoulos; Panagiotis Malandrakis; Nikolaos Kanellias; Evangelos Eleutherakis‐Papaiakovou; Magdalini Migkou; Vasiliki Spiliopoulou; Ilias Katsadouros; Aikaterini Vlachou; Despina Fotiou; Konstantinos Giannakas; Erasmia Boutakoglou; Stavroula Giannouli; Panagiotis Tsirigotis; Asimina Papanikolaou; Evangelos Terpos; Meletios A. DimopoulosShow moreShow less
Affiliations
1. Department of Clinical Therapeutics, Alexandra General Hospital National and Kapodistrian University of Athens Athens Greece; 2. 2nd Department of Internal Medicine, “Hippokration” General Hospital National and Kapodistrian University of Athens Athens Greece; 3. 2nd Department of Internal Medicine ATTIKON General University Hospital, Hematology Division, National and Kapodistrian University of Athens Athens Greece; 4. Department of Haemopathology “Evangelismos” Hospital Athens GreeceShow moreShow less
83
days
First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma
Authors
Umberto Vitolo; Lorenzo Falchi; Per‐Ola Andersson; Marcel Nijland; Fritz Offner; Sylvia Snauwaert; Jacob H. Christensen; Michael R. Clausen; Alexander Fosså; Pilar G. Prieto; Eliza A. Hawkes; Judit M. Jørgensen; Yasmin H. Karimi; Catharina Lewerin; Joost S. P. Vermaat; Björn E. Wahlin; Poliana Patah; Christopher Morehouse; Malene Risum; Zhu Li; Jennifer Marek; Joshua D. BrodyShow moreShow less
Affiliations
1. Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia‐IRCCS Candiolo (Turin) Piedmont Italy; 2. Lymphoma Service, Memorial Sloan Kettering Cancer Center New York New York USA; 3. Section for Hematology and Coagulation Sahlgrenska University Hospital Gothenburg Sweden; 4. Department of Hematology University Medical Center Groningen and University of Groningen Groningen Netherlands; 5. Department of Hematology Universitair Ziekenhuis Gent Ghent Belgium; 6. Department of Hematology AZ Sint‐Jan Hospital Bruges Belgium; 7. Department of Hematology Odense University Hospital Odense Denmark; 8. Department of Hematology and University of Southern Denmark Vejle Hospital Vejle Denmark; 9. Department of Oncology Oslo University Hospital Oslo Norway; 10. Department of Hematology IdiPaz, La Paz University Hospital Madrid Spain; 11. Olivia Newton John Cancer Research Institute at Austin Health Melbourne Victoria Australia; 12. Department of Haematology Aarhus University Hospital Aarhus Midtjylland Denmark; 13. Division of Hematology‐Oncology, Department of Medicine University of Michigan Ann Arbor MI USA; 14. Department of Hematology and Coagulation, Sahlgrenska University Hospital University of Gothenburg Gothenburg Götaland Sweden; 15. Department of Hematology Leiden University Medical Center Leiden Zuid‐Holland Netherlands; 16. Department of Hematology Karolinska Institutet Stockholm Stockholms län Sweden; 17. AbbVie North Chicago Illinois USA; 18. Genmab Plainsboro New Jersey USA; 19. Genmab Copenhagen Hovedstaden Denmark; 20. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York New York USAShow moreShow less
84
days
Therapeutic success and epidemiological failure in hematology
Authors
Pierre SujobertShow moreShow less
Affiliations
1. Hospices Civils de Lyon, Hôpital Lyon Sud, Service d'hématologie biologique Lyon France; 2. Faculté de médecine et de maïeutique Lyon Sud Charles Mérieux, Lymphoma Immunobiology Team, Université Claude Bernard Lyon 1 Oullins‐Pierre Bénite FranceShow moreShow less
5
days
Shooting the messenger: Ecosystem approaches in haematology
Authors
Stephen P. HibbsShow moreShow less
Affiliations
1. Wolfson Institute of Population Health Queen Mary University of London London United KingdomShow moreShow less
129
days
Clonal and genomic determinants of e1a2 BCR::ABL1 chronic myeloid leukemia: A Fi‐LMC study
Authors
Benjamin Podvin; Olivier Nibourel; Sandrine Hayette; Valérie Coiteux; Rathana Kim; Lucie Rigolot; Stéphanie Dulucq; Augustin Boudry; Geoffrey Pawlak; Wayne‐Corentin Lambert; Pascale Flandrin‐Gresta; Ivan Sloma; Christophe Roumier; Marie Balsat; Sandrine Loron; Chloé Li; Sandrine Geffroy; Jean‐Michel Cayuela; Françoise Huguet; François‐Xavier Mahon; Franck E. Nicolini; Delphine Réa; Claude Preudhomme; Nicolas Duployez; Catherine Roche‐Lestienne; Fi‐LMC groupShow moreShow less
Affiliations
1. Laboratory of Hematology CHU Lille Lille France; 2. PERSTIM Lab, CRC Lille University of Lille, Inserm Lille France; 3. Institut Bergonié, Fi‐LMC Bordeaux France; 4. Laboratory of Hematology and Molecular Biology, CHU Lyon Sud Pierre‐Bénite France; 5. Hematology Department Huriez Hospital, CHU Lille Lille France; 6. Hematology Laboratory University Hospital Saint‐Louis, AP‐HP and EA3518, Université Paris Cité Paris France; 7. Université Paris Cité, UMR 1342, Institut de Recherche Saint‐Louis, Leukemia Institute Paris Saint‐Louis Paris France; 8. Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole Toulouse France; 9. Laboratory of Hematology, University Hospital of Bordeaux, INSERM U1312 France; 10. ULR 2694 Metrics, Centre Hospitalier Universitaire de Lille Université de Lille Lille France; 11. Laboratory of Hematology, University Hospital of Brest Brest France; 12. Hematology Laboratory University Hospital of Saint‐Etienne St Etienne France; 13. Hematology and Immunology Department AP‐HP Henri Mondor Créteil France; 14. Hematology Department CHU Lyon Sud Lyon France; 15. Hematology Department Hopital National d'Instruction des Armées Percy Clamart France; 16. Hematology Department Institut Universitaire du Cancer de Toulouse Toulouse France; 17. Institut Bergonié Bordeaux, Unicancer Aquitaine France; 18. INSERM Lyon France; 19. Hematology Department Centre Léon Bérard Lyon France; 20. Adult Hematology Department Saint Louis University Hospital Paris France; 21. Genetics Medical Institute, Hopital Jeanne de Flandre Lille FranceShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days